Sirona Biochem Announces Successful Synthesis Of Anti-Inflammatory Compound For Bloom Burton & Co. Joint Venture

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, BC--(Marketwired - July 31, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton") Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.

At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. Sirona and Bloom Burton are identifying and designing a library of compounds to address these substantial markets which combined reach nearly $2 Billion US each year globally. Sirona is responsible for the chemistry and Bloom Burton for the financing, clinical validation as well as the commercialization of the compounds.

"We could not be more pleased with the completion of the first synthetic compounds. This is a major milestone in the development of our portfolio for rare and neglected diseases," said Howard Verrico, CEO of Sirona Biochem. "The team at Bloom Burton will plan for the testing of our new anti-inflammatory compounds in the near future. In the next several months, we will be working on the development of further compounds for our JV with Bloom Burton as planned."

About Bloom Burton & Co.

Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:
Christopher Hopton
Sirona Biochem Corp.
Phone: 1.604.282.6064

Help employers find you! Check out all the jobs and post your resume.

Back to news